# A Case of Hepatic Tuberculosis in a Patient on Adalimumab for Ankylosing Spondylitis

## TL;DR

This paper reports a rare case of liver tuberculosis in a patient taking adalimumab for ankylosing spondylitis.

## Contribution

The novelty lies in documenting hepatic TB in a patient on adalimumab, highlighting risks in immunosuppressed individuals.

## Key findings

- Hepatic TB is uncommon and often secondary to other TB sources.
- Immunosuppressive therapy, like adalimumab, increases the risk of TB.
- This case emphasizes the need for TB screening in patients on immunosuppressants.

## Abstract

Hepatic tuberculosis (TB) is an uncommon extrapulmonary manifestation of tuberculosis. Hepatic TB is more common in immunocompromised patients, such as those on immunosuppressive medications or those with a human immunodeficiency virus (HIV) infection. Primary hepatic TB is rare, and liver involvement is often secondary to spreading from the lymphatics, portal vein, or hepatic artery. We report a case of hepatic TB in a patient on adalimumab for ankylosing spondylitis (AS).